Prelude Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Prelude Therapeutics Inc. - overview
Established
2016
Location
Wilmington, DE, US
Primary Industry
Biotechnology
About
Prelude Therapeutics Inc. , based in Wilmington, US, focuses on precision oncology by developing innovative medicines to meet critical needs in cancer treatment, emphasizing targeted therapies. Founded in 2016 and headquartered in Wilmington, US, Prelude Therapeutics Inc. specializes in precision oncology.
The company has engaged in 7 deals, with its most recent funding round being a Private Placement/Follow on, raising USD 100. 00 mn in total. The latest funding round occurred on December 11, 2023, aimed at supporting the development of its innovative drug pipeline. The company is led by CEO Kris Vaddi, who has a background in biotechnology and has previously founded and led other ventures.
Prelude Therapeutics specializes in precision oncology, focusing on the development of innovative medicines aimed at addressing high unmet needs in cancer treatment. The company’s core product offerings include first-in-class, highly selective SMARCA2 and KAT6A degraders, designed to target specific oncogenic drivers and enhance treatment efficacy in cancers such as ER+ breast cancer and other solid tumors. These degrader molecules are part of a broader portfolio that also encompasses next-generation degrader antibody conjugates and selective CDK inhibitors, including CDK9 and CDK4/6 inhibitors. Prelude Therapeutics primarily serves healthcare providers, oncologists, and pharmaceutical partners in established markets including North America and Europe, aiming to improve patient outcomes through tailored cancer therapies.
Prelude Therapeutics generated revenue of USD 7. 00 mn in the most recent year, 2024, with an EBITDA of USD -136. 85 mn. The company primarily generates income through partnerships with pharmaceutical companies and research institutions, focusing on collaborative drug development, and enters agreements involving milestone payments and royalties based on successful commercialization.
In December 2023, Prelude Therapeutics Inc. raised USD 25 mn in a private placement, selling 7. 9 million shares at USD 3. 15 per share on the NASDAQ.
The funds will support the ongoing development of upcoming products, including innovative cancer therapies targeted for release in the near future. The company aims to expand its reach into new markets, specifically targeting regions in Europe and Asia by 2025, enhancing its global footprint in precision oncology.
Current Investors
OrbiMed Advisors, Fidelity Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.preludetx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Prelude Therapeutics Inc. - timeline of key events
Prelude Therapeutics Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (14,800,000) | (27,727,000) | (58,221,000) | (111,456,000) | (119,625,000) | - | - | - |
| Operating Income (USD) | (15,000,000) | (28,109,000) | (58,763,000) | (113,735,000) | (123,540,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - |
| NET Income (USD) | (14,700,000) | (27,570,000) | (56,929,000) | (111,694,000) | (115,438,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - |
Prelude Therapeutics Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.